Jul 30 2012
REDWOOD CITY, Calif.—(BUSINESS WIRE)—Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients’ health habits and connections to caregivers.
Proteus has worked collaboratively with the FDA since 2008 to determine the regulatory pathway for this innovation, which represents a new category of medical device and patient care. The application was ultimately processed in accordance with the de novo provisions of the Federal Food, Drug and Cosmetic Act for low-risk devices that have no predicate on the market.
“We are thrilled to have achieved this important milestone to market our ingestible sensor in the United States now, as well as in Europe,” said Dr. George M. Savage, co-founder and chief medical officer at Proteus Digital Health. “We are very much looking forward to bringing the benefits of our ingestible sensor to the American public in the form of innovative product offerings.”
“The FDA validation represents a major milestone in digital medicine. Directly digitizing pills, for the first time, in conjunction with our wireless infrastructure, may prove to be the new standard for influencing medication adherence and significantly aid chronic disease management,” said Dr. Eric Topol, professor of genomics at The Scripps Research Institute and author of “The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Healthcare”.
The Proteus ingestible sensor can be integrated into an inert pill or other ingested products, such as pharmaceuticals. Once the ingestible sensor reaches the stomach, it is powered by contact with stomach fluid and communicates a unique signal that determines identity and timing of ingestion. This information is transferred through the user’s body tissue to a patch worn on the skin that detects the signal and marks the precise time an ingestible sensor has been taken. Additional physiologic and behavioral metrics collected by the patch include heart rate, body position and activity. The patch relays information to a mobile phone application. With the patient’s consent, the information is accessible by caregivers and clinicians, helping individuals to develop and sustain healthy habits, families to make better health choices, and clinicians to provide more effective, data-driven care.
About Proteus Digital Health
Proteus Digital Health, Inc. is developing and commercializing digital health feedback technology that is integrated into ingestible products. This provides an unprecedented view into an individual’s personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians, while enabling new information-based business models. Proteus received a CE mark in August 2010 and U.S. FDA approval in July 2012 for its technology platform. Headquartered in Redwood City, Calif., Proteus is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, ON Semiconductor and other investors. For more information please visit www.proteusdigitalhealth.com.
Read more: Proteus Digital Health Announces FDA Clearance of Ingestible Sensor - FierceMedicalDevices http://www.fiercemedicaldevices.com/press-releases/proteus-digital-health-announces-fda-clearance-ingestible-sensor?utm_medium=nl&utm_source=internal#ixzz228EEzBzd